Ariad Pharmaceuticals Inc. (ARIA)
-NasdaqGS 16.67 
0.20(1.21%) May 17, 4:00PM EDT|After Hours
:
16.47 0.20 (1.20%) May 17, 4:06PM EDT
| Prev Close: | 16.47 |
|---|
| Open: | 16.61 |
|---|
| Bid: | 16.11 x 500 |
|---|
| Ask: | 16.94 x 500 |
|---|
| 1y Target Est: | 27.95 |
|---|
| Beta: | 1.32 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 16.40 - 16.85 |
|---|
| 52wk Range: | 15.13 - 25.40 |
|---|
| Volume: | 3,261,521 |
|---|
| Avg Vol (3m): | 3,028,810 |
|---|
| Market Cap: | 3.06B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Analysts: Tesla’s Capital Efforts Are Beneficial and 3 More Research Notes to Readat Wall St. Cheat Sheet(Fri, May 17)
- ARIAD PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- 3 Companies That Put the "Tech" in "Biotech"at Motley Fool(Thu, May 16)
- BlackBerry Overtaken By Windows Phone and 2 Other Hot Stocks to Watchat Wall St. Cheat Sheet(Thu, May 16)
- Ariad Stock Falls On Unusually High Volume (ARIA)at TheStreet(Thu, May 16)
- ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual MeetingBusiness Wire(Wed, May 15)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Wed, May 15)
- New cancer tools allow patients to reconsider chemoat Reuters(Wed, May 15)
- ARIAD Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Tue, May 14)
- 2 Biotech Companies With Strong Product Launches To Monitorat Seeking Alpha(Tue, May 14)
- ARIAD to Present at UBS Global Healthcare ConferenceBusiness Wire(Mon, May 13)
- ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sectorat Seeking Alpha(Thu, May 9)
- Ariad Posts Wider Y/Y LossZacks(Wed, May 8)
- Does Ariad's Leukemia Drug Have Hidden Potential?at Motley Fool(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 436.17 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.67 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -0.99 |
|---|
Business Summary
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing addition...
View More